Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Northern Trust Corp

Northern Trust Corp boosted its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 9.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 187,017 shares of the company’s stock after purchasing an additional 16,299 shares during the quarter. Northern Trust Corp owned about 0.63% of Disc Medicine worth $11,857,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its holdings in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after purchasing an additional 503 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after purchasing an additional 266 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Disc Medicine in the fourth quarter valued at approximately $235,000. Teacher Retirement System of Texas boosted its holdings in Disc Medicine by 8.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock valued at $308,000 after purchasing an additional 396 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $309,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Stock Performance

IRON stock opened at $48.09 on Friday. Disc Medicine, Inc. has a one year low of $30.65 and a one year high of $68.73. The stock has a market capitalization of $1.66 billion, a PE ratio of -12.08 and a beta of 0.77. The company has a fifty day moving average of $46.10 and a 200-day moving average of $54.88.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Equities analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IRON shares. BMO Capital Markets increased their price objective on Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, May 12th. Cantor Fitzgerald increased their price objective on Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th. Scotiabank increased their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, Wedbush reissued an “outperform” rating and issued a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $98.80.

Insider Transactions at Disc Medicine

In other news, insider Pamela Stephenson sold 3,137 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,217.46. Following the completion of the transaction, the insider now owns 69,529 shares in the company, valued at $3,794,892.82. This trade represents a 4.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William Jacob Savage sold 2,100 shares of the stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the transaction, the insider now owns 66,398 shares of the company’s stock, valued at $3,331,187.66. This represents a 3.07% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 356,290 shares of company stock worth $19,336,901. Company insiders own 4.24% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.